The University of Chicago Medicine Comprehensive Cancer Center, Chicago
UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
UChicago Medicine Orland Park, Orland Park

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT05868226

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Orchard Healthcare Research Inc.- Skokie, Skokie

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT06324357

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Northwestern Medicine Chicago Proton Center, Warrenville

A’ fastadhÌre 2

Aoisean 50 agus nas sine · Banairean · Air ùrachadh 29 Sult 2026 · NCT01766297

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

The University of Chicago Medicine Comprehensive Cancer Center, Chicago

A’ fastadh

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07553234

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Rush University Medical Center ( Site 0079), Chicago

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06312176

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, Chicago

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

City of Hope Chicago, Zion

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07007559

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Northwestern University, Chicago

A’ fastadh

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07214532

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Peoria
Clinical Trial Site, Urbana

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07085767

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

City of Hope, Chicago, Chicago
Northwestern Memorial Hospital, Chicago
University of Illinois at Chicago, Chicago
agus 3 a bharrachd

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07174336

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

University of Chicago, Chicago

A’ fastadhFàilte do shaor-thoilich fhallain

Aoisean 30 gu 74 · Banairean · Air ùrachadh 21 Sult 2026 · NCT02620852

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

University of Illinois Hospital & Health Sciences System, Chicago

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06827236

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Cancer Care Specialists, Decatur
Cancer Care Specialists of Illinois, O'Fallon
Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

City of Hope, Chicago, Zion

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07109726

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Illinois Cancer Specialists, Arlington Heights
Northwestern Memorial Hospital, Chicago
RUSH MD Anderson Cancer Center, Chicago

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT06492616

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Orchard Healthcare Research Inc., Skokie

A’ fastadhSgrùdadh amharc

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT05935384

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope® Cancer Center Chicago, Zion

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT03424005

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Orchard Healthcare Research Inc. ( Site 0006), Skokie

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT06797635

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

University of Illinois Cancer Center, Chicago
University of Chicago Medicine, Chicago
City of Hope - Chicago, Zion

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

University of Chicago, Chicago

A’ fastadhÌre 1

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06253871

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

NorthShore University Health System - Evanston Hospital, Evanston
NorthShore University HealthSystem - Evanston Hospital, Evanston
Duly Health and Care, Lisle
agus 2 a bharrachd

A’ fastadhÌre 1

Aoisean 18 gu 55 · Banairean · Air ùrachadh 9 Sult 2026 · NCT07310420

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Carle Cancer Center, Urbana

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT05386108

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site, Evanston

A’ fastadhÌre 3

Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT07647328

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

City of Hope® Cancer Center Chicago, Zion

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT07100106

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Northwestern University, Chicago

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT05315700

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Northwestern University, Chicago
Rush University Medical Center, Chicago
University of Chicago, Chicago

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT06062498

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Cancer Care Specialists of Central Illinois, O'Fallon
Springfield Clinic, Springfield
Carle Cancer Center, Urbana
agus 1 a bharrachd

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT06790693

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

University of Illinois Cancer Center, Chicago

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT04886531

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Southern Illinois Hospital Services, Carbondale
Cancer Care Specialist of Illinois, O'Fallon

A’ fastadhSgrùdadh amharc

Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT07211178

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Northwestern University, Chicago
Southern Illinois University-Simmons, Springfield
Carle Foundation Cancer Institute-Urbana, Urbana

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06072612

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

OSF Saint Anthony's Health Center, Alton
Advocate Outpatient Center - Aurora, Aurora
Advocate Good Shepherd Hospital, Barrington
agus 83 a bharrachd

A’ fastadhÌre 3

Aoisean 18 gu 60 · Banairean · Air ùrachadh 2 Sult 2026 · NCT05879926

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

University Of Chicago Medicine Comprehensive Cancer Center, Chicago

A’ fastadhFàilte do shaor-thoilich fhallain

Aoisean 25 agus nas sine · Banairean · Air ùrachadh 1 Sult 2026 · NCT03729115

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

University of Chicago Medical Center, Chicago

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 26 Lùna 2026 · NCT06533826

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.